Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 8/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 7/20 | 0.41 |
| ▸ | DHODH | Q02127 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | MPO | P05164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1998284 | 0.84 | F10 (0.43) | CYP11B2CYP11B1DHODHGPR119BRD4 | |
| SCHEMBL6494664 | 0.81 | GPR119 (0.41) | CYP11B2DHODHGPR119BRD4MPO | |
| SCHEMBL30681413 | 0.78 | GPR119 (0.49) | CYP11B2CYP11B1DHODHGPR119BRD4 | |
| SCHEMBL994201 | 0.78 | CYP11B1 (0.43) | CYP11B2CYP11B1GPR119HTR2C | |
| SCHEMBL5626038 | 0.77 | CYP11B2 (0.44) | CYP11B2CYP11B1HTR2CHTR2A | |
| SCHEMBL5626045 | 0.77 | CYP11B2 (0.47) | CYP11B2CYP11B1HTR2CHTR2A | |
| SCHEMBL6506289 | 0.77 | F10 (0.52) | CYP11B2DHODHGPR119BRD4MPO | |
| SCHEMBL8340084 | 0.77 | CYP1A2 (0.46) | CYP11B2CYP11B1HTR2CHTR2A | |
| SCHEMBL6492585 | 0.77 | F10 (0.53) | CYP11B2DHODHGPR119MPO | |
| SCHEMBL30681471 | 0.76 | DRD3 (0.46) | DHODHGPR119BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070179122-A1 | Beta-Aminoacid-Derivatives As Factor Xa Inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-02 | — | — | US | disclosed |
| EP-1723164-A1 | BETA-AMINOACID-DERIVATIVES AS FACTOR Xa INHIBITORS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-11-22 | — | — | EP | disclosed |
| WO-2005095440-A1 | BETA-AMINOACID-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-10-13 | — | — | WO | disclosed |
| EP-1571154-A1 | Beta-aminoacid-derivatives as factor Xa inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2005-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179122-A1 | Beta-Aminoacid-Derivatives As Factor Xa Inhibitors | F12, F11, F5 | CYP11B2 3430/4885CYP11B1 3225/4885DHODH 3446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.